ABCA1 Expression Biomarker for Prostate Cancer Severity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively address the progression and aggressiveness of prostate cancer, particularly in relation to intracellular cholesterol levels, which are critical for de novo androgen synthesis and AKT signaling.
Innovation Solution
The method involves determining the expression levels of the ABCA1 protein or mRNA in urine or prostate samples, using immunoassays with specific antibodies, and analyzing promoter methylation to assess the severity of prostate cancer, with decreased ABCA1 expression indicating more severe cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and treatment methods are used for prostate cancer, then standard care is provided, but the progression and aggressiveness of prostate cancer cannot be effectively addressed
Solution Approach 1:
The patent applies parameter changes by measuring ABCA1 expression levels as a biomarker to stratify patients into different risk categories. This enables tailoring of treatment intensity and monitoring frequency based on individual patient characteristics, thereby improving treatment effectiveness while adapting to varying cancer aggressiveness. The approach transforms a one-size-fits-all treatment model into a personalized medicine framework.
2Measurement precision
If ABCA1 expression levels are measured to assess prostate cancer severity, then prognosis and diagnosis accuracy is improved, but additional testing requirements increase
Solution Approach 1:
The patent uses ABCA1 expression level as an intermediary biomarker that connects tumor biology to clinical outcomes. By measuring this single molecular parameter, the patent indirectly assesses multiple aspects of cancer behavior including progression risk, response to therapy, and overall prognosis. This intermediary approach simplifies complex diagnostic needs into a single measurable parameter.
3Stability of the object's composition
If intracellular cholesterol levels are allowed to remain high to support cell membrane structure, then cell integrity is maintained, but de novo androgen synthesis and AKT signaling are enhanced promoting cancer progression
Solution Approach 1:
The patent implements a feedback mechanism by measuring ABCA1 expression levels to monitor intracellular cholesterol homeostasis status. Based on this information, clinicians can adjust therapeutic interventions to maintain cholesterol levels within a therapeutic window that preserves membrane integrity while preventing excessive cholesterol accumulation that would drive androgen synthesis and AKT signaling. This feedback loop enables dynamic adjustment of treatment to balance structural needs against cancer progression risks.
Data Source
AI summary
A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.